STOCK TITAN
  1. Home
  2. News
  3. NVRO

Nevro Corp - NVRO STOCK NEWS

Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.

Nevro Corp (NYSE: NVRO), a pioneer in neuromodulation therapies for chronic pain management, provides this centralized hub for investors and healthcare professionals to access its latest developments. Track official press releases, clinical milestones, and business updates from the creator of the Senza spinal cord stimulation system.

This resource delivers timely updates on NVRO's FDA clearances, international expansions, and evidence-based innovations like its AI-enhanced HFX platform. Users will find disclosures covering product launches, financial results, and strategic partnerships that shape chronic pain treatment globally.

Key updates include advancements in 10 kHz therapy clinical applications, regulatory approvals across markets, and operational developments impacting patient access. Bookmark this page to stay informed about Nevro's progress in redefining neuromodulation standards through engineering and clinical excellence.

News

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results

Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) announced its preliminary, unaudited fourth-quarter and full-year 2023 revenue results, with worldwide revenue exceeding expectations at $116.0 million for Q4 and $425.0 million for the full year. The company also announced a restructuring, including laying off 5% of its workforce, to support long-term growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
News

Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company's management team will deliver a formal presentation at 8:15 am PST (11:15 am EST). A live webcast and replay of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
-
News

Nevro Announces Acquisition of Vyrsa™ Technologies

Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) refinances with a $200M structured debt maturing in 2029, acquires Vyrsa Technologies, and closes a $200 million term loan credit facility. Vyrsa is projected to be accretive to Nevro in 2024 for both revenue and AEBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.66%
Tags
acquisition
News

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) - Nevro Corp. announces the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) multicenter randomized controlled trial (RCT) in the Journal of Neurosurgery: Spine. The data show that patients in the high-frequency SCS arm experienced profound improvements in pain, function, and quality of life, plus reduced opioid use compared to the CMM arm at 24 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

Rhea-AI Summary
Nevro Corp. reported its third quarter 2023 financial results, with worldwide revenue of $103.9 million, a 3% growth compared to the same period last year. Painful Diabetic Neuropathy (PDN) indication sales grew 56% to approximately $20.8 million. The company provided fourth quarter revenue guidance of $108 million to $110 million and updated its full-year 2023 revenue guidance to $417 million to $419 million, representing 3% constant currency growth over 2022. The net loss from operations in the third quarter was $25.6 million, and the non-GAAP adjusted EBITDA loss was $5.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
earnings
-
News

Nevro to Report Third Quarter 2023 Financial Results

Rhea-AI Summary
Nevro Corp. to report Q3 2023 financial results on Nov 1, 2023. Conference call scheduled at 1:30 pm PT/ 4:30 pm ET. Webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
conferences earnings
News

New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy

Rhea-AI Summary
Nevro Corp. announces publication of data validating the health economic benefits of 10 kHz Therapy for chronic pain treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
News

Nevro Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary
Nevro Corp. to present at Wells Fargo Healthcare Conference and Morgan Stanley Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences
-
News

New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Rhea-AI Summary
Nevro Corp. announces publication of 24-month data from SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial, showing long-term efficacy of high-frequency 10 kHz SCS in treating PDN. Patients experienced durable pain relief, improved quality of life, and better sleep. Neurological symptoms also improved. The study confirms the safety and effectiveness of 10 kHz SCS as a therapy for PDN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
News

Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance

Rhea-AI Summary
Nevro Corp. reported second quarter 2023 financial results, with worldwide revenue of $108.8 million, a 4% increase compared to the same period in 2022. Painful Diabetic Neuropathy (PDN) indication sales grew 73% to approximately $19.0 million. The company also provided third quarter revenue guidance of $95 million to $97 million and updated its full-year 2023 revenue guidance to $410 million to $415 million, representing 1% to 2% constant currency growth over 2022. Additionally, Nevro announced the appointment of Greg Siller as the new Chief Commercial Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.69%
Tags
earnings
Stock NVRO logo
Nevro Corp

NYSE:NVRO

NVRO Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NVRO Stock Data

221.21M
37.30M
2.88%
104.91%
4.81%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
REDWOOD CITY